<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="iso-abbrev">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of the American Pharmacists Association : JAPhA</journal-title></journal-title-group><issn pub-type="ppub">1544-3191</issn><issn pub-type="epub">1544-3450</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10198806</article-id><article-id pub-id-type="pmcid-ver">PMC10198806.1</article-id><article-id pub-id-type="pmcaid">10198806</article-id><article-id pub-id-type="pmcaiid">10198806</article-id><article-id pub-id-type="manuscript-id">NIHMS1871338</article-id><article-id pub-id-type="pmid">36872182</article-id><article-id pub-id-type="doi">10.1016/j.japh.2023.01.013</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1871338</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1871338</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>&#8220;LIKE IT WAS JUST EVERYDAY BUSINESS&#8221;: A QUALITATIVE STUDY OF PHARMACY-BASED NALOXONE AND SYRINGE CUSTOMER EXPERIENCE</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gray</surname><given-names initials="M">Mary</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shin</surname><given-names initials="SS">Sarah S.</given-names></name><degrees>MA</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silcox</surname><given-names initials="J">Joseph</given-names></name><degrees>MA</degrees><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Flores</surname><given-names initials="D">Diana</given-names></name><degrees>BS</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bolivar</surname><given-names initials="D">Derek</given-names></name><degrees>BS</degrees><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Irwin</surname><given-names initials="AN">Adriane N.</given-names></name><degrees>MS, PharmD</degrees><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Floyd</surname><given-names initials="AS">Anthony S.</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bratberg</surname><given-names initials="J">Jeffrey</given-names></name><degrees>PharmD</degrees><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boggis</surname><given-names initials="JS">Jesse S.</given-names></name><degrees>MPH</degrees><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hartung</surname><given-names initials="DM">Daniel M</given-names></name><degrees>PharmD, MPH</degrees><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Green</surname><given-names initials="TC">Traci C.</given-names></name><degrees>PhD, MSc</degrees><xref rid="A2" ref-type="aff">b</xref><xref rid="A7" ref-type="aff">g</xref></contrib></contrib-group><aff id="A1"><label>a</label>Comagine Health, Portland, OR</aff><aff id="A2"><label>b</label>Opioid Policy Research Collaborative, The Heller School for Social Policy and Management, Brandeis University, Waltham, MA</aff><aff id="A3"><label>c</label>Oregon State University College of Pharmacy, Corvallis, OR</aff><aff id="A4"><label>d</label>University of Washington, School of Medicine, Addictions, Drug, &amp; Alcohol Institute, Seattle, WA</aff><aff id="A5"><label>e</label>University of Rhode Island College of Pharmacy, Kingston, RI</aff><aff id="A6"><label>f</label>The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College, Lebanon, NH</aff><aff id="A7"><label>g</label>COBRE on Opioids and Overdose and the Department of Emergency Medicine, Rhode Island Hospital, Providence, RI</aff><author-notes><fn fn-type="con" id="FN2"><p id="P1"><bold>Author contributions:</bold> Boggis &#8211; investigation, methodology, supervision, project administration, writing &#8211; review &amp; editing; Bolivar &#8211; data curation, visualization, writing &#8211; review &amp; editing; Bratberg &#8211; conceptualization, investigation, writing &#8211; review &amp; editing; Flores &#8211; data curation, writing &#8211; review &amp; editing; Floyd &#8211; investigation, project administration, writing &#8211; review &amp; editing; Gray &#8211; data curation, formal analysis, methodology, project administration, writing &#8211; original draft; Green &#8211; conceptualization, funding acquisition, methodology, writing &#8211; review &amp; editing; Hansen &#8211; funding acquisition, writing &#8211; review &amp; editing; Hartung &#8211; funding acquisition, writing &#8211; review &amp; editing; Irwin &#8211; funding acquisition, investigating, writing &#8211; review &amp; editing; Shin &#8211; data curation, formal analysis, methodology, project administration, writing &#8211; original draft; Silcox &#8211; data curation, methodology, project administration, writing &#8211; review &amp; editing.</p></fn><corresp id="CR1"><bold>Corresponding Author:</bold> Traci C. Green, PhD, MSc, Professor and Director, Opioid Policy Research Collaborative, Heller School for Social Policy and Management, Brandeis University, 415 South Main St., MS035, Waltham MA 02454, <email>Traci.c.green@gmail.com</email>, (617) 909-9919 (phone)</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>1</month><year>2023</year></pub-date><issue-id pub-id-type="pmc-issue-id">436236</issue-id><elocation-id>S1544-3191(23)00011-0</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>04</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 11:25:31.053"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1871338.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P2">As rates of overdoses involving opioids continue to rise in the US, community pharmacies are uniquely positioned as a central access point of care for individuals to access harm reduction supplies, such as naloxone and non-prescription syringes (NPS).</p></sec><sec id="S2"><title>Objectives:</title><p id="P3">This study aims to identify the facilitators and barriers of obtaining naloxone and NPS at community pharmacies that participated in <italic toggle="yes">Respond to Prevent</italic> (R2P), a multi-component intervention to increase dispensing rates of naloxone, buprenorphine, and NPS.</p></sec><sec id="S3"><title>Methods:</title><p id="P4">Pharmacy customers were recruited to participate in semi-structured qualitative interviews conducted immediately after they obtained, or attempted to obtain, naloxone and NPS (when applicable) from R2P-participating pharmacies. Thematic analysis was conducted on the transcribed interviews and content coding was applied to ethnographic notes and text messages from participants.</p></sec><sec id="S4"><title>Results:</title><p id="P5">Of the 32 participants, most (n=28, 88%) successfully obtained naloxone and the majority (n=14, 82%) of those seeking NPS successfully purchased them as well. Participants reported positive overall experiences at the community pharmacies. Participants described using the intervention advertising materials, as designed, to facilitate the request for naloxone. Many participants shared that they felt respected by pharmacists, and that they valued naloxone counseling sessions that were tailored to meet their needs and allowed space for them to ask questions. Barriers included experiences where the intervention did not address structural challenges that prohibited the purchase of naloxone and where certain types of staff lacked knowledge, treated participants poorly, or did not adequately provide expected naloxone counseling.</p></sec><sec id="S5"><title>Conclusion:</title><p id="P6">Pharmacy customer experiences obtaining naloxone and NPS in R2P-participating pharmacies identify facilitators and barriers to access that may be used to reform implementation and future interventions. Barriers identified can help enhance strategies or inform policies to improve pharmacy-based harm reduction supply distribution not addressed through existing interventions.</p></sec></abstract><kwd-group><kwd>Pharmacy</kwd><kwd>pharmacist</kwd><kwd>naloxone</kwd><kwd>syringes</kwd><kwd>harm reduction</kwd><kwd>drug overdose</kwd><kwd>qualitative</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>